2'-cyano-2'-deoxyarabinofuranosylcytosine has been researched along with Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eshima, K; Fukushima, M; Iizuka, K; Jin, C; Zhang, C | 1 |
| Benhadji, K; Calvo, F; Chiao, J; Cvitkovic, E; Faivre, S; Galmarini, CM; Ghoul, A; Green, SR; Le Tourneau, C; Raymond, E; Serova, M | 1 |
| Matsuda, A | 1 |
| Matsuda, A; Sasaki, T | 1 |
1 review(s) available for 2'-cyano-2'-deoxyarabinofuranosylcytosine and Neoplasms
| Article | Year |
|---|---|
[Why is the DNA-strand-breaker, PCNDAC, effective to solid tumors?].
Topics: Animals; Apoptosis; Cytarabine; DNA Damage; DNA, Neoplasm; Drug Design; Gene Deletion; Genes, p53; Humans; Mice; Mice, Nude; Necrosis; Neoplasms; Point Mutation; Prodrugs; RNA, Neoplasm | 1998 |
3 other study(ies) available for 2'-cyano-2'-deoxyarabinofuranosylcytosine and Neoplasms
| Article | Year |
|---|---|
Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Infusions, Intravenous; Isoflurophate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2018 |
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Topics: 5'-Nucleotidase; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids | 2007 |
[Design of a new antitumor nucleoside CNDAC, against solid tumors].
Topics: Antineoplastic Agents; Cytarabine; DNA Damage; DNA Polymerase II; DNA, Neoplasm; Drug Design; Drug Screening Assays, Antitumor; Humans; Neoplasms | 1996 |